User login
Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).
Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.
Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.
Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.
Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi: 10.1053/j.gastro.2022.06.020
Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).
Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.
Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.
Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.
Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi: 10.1053/j.gastro.2022.06.020
Key clinical point: Fecal microbiota transplantation (FMT) was safe and effective with effects sustained for at least 3 years after transplantation in patients with irritable bowel syndrome (IBS).
Major finding: Patients who received 30 or 60 g feces vs placebo showed a significantly higher response rate and significantly lower IBS-Severity Scoring System scores at 2 and 3 years after FMT (all P ≤ .05). No adverse event other than mild intermittent abdominal pain, diarrhea, and constipation within the first 2 days after FMT were reported.
Study details: Findings are from a 3-year follow-up study of 125 patients with IBS who underwent FMT and were randomly assigned to receive placebo (own feces) or donor feces (30 or 60 g); feces were administered to the duodenum.
Disclosures: This study was supported by Helse Fonna. The authors declared no conflicts of interest.
Source: El-Salhy M et al. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at three years after transplantation. Gastroenterology. 2022 (Jun 13). Doi: 10.1053/j.gastro.2022.06.020